Bortezomib Injection
for subcutaneous use Initial U.S. Approval: 2003

bortezomib is a proteasome inhibitor indicated for:
• treatment of patients with multiple myeloma
• treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.

Facts about Bortezomib for Injection

Approval Date: 2003
Proprietary Name: On Request
Active Ingredient(s): Bortezomib for Injection
Dosage Forms And Strengths:
Manufacturer:
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “Bortezomib for Injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.